|
Oct 9
|
Lumos Pharma Inc (LUMO) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Prudence
|
|
Sep 5
|
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
|
|
Jul 23
|
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
|
|
Apr 18
|
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
|
|
Feb 5
|
Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Invest In Growth?
|
|
Nov 7
|
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
|
|
Nov 7
|
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
|
|
Aug 9
|
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
|
|
Apr 27
|
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
|